stockrowLiquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
Follow LQDA
Alert me
Liquidia Corporation (LQDA) Return on equity
Liquidia Corporation's return on equity over the twelve months to 30 June 2026 was 131.8%, up 242.9 percentage points from fiscal 2025 (−111.1%). Over the past ten years it has ranged from −202.6% (fiscal 2024) to 706.2% (fiscal 2018); the current reading is higher than 31% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −111.1% | 91.51 |
| FY2024 | −202.6% | (88.55) |
| FY2023 | −114.0% | (61.32) |
| FY2022 | −52.7% | (52.69) |
| FY2022 | 0.00% | 50.72 |
| FY2021 | −50.7% | (50.72) |
| FY2021 | 0.00% | 112.72 |
| FY2020 | −112.7% | (112.72) |
| FY2020 | 0.00% | 177.43 |
| FY2019 | −177.4% | (177.43) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LQDA Liquidia Corporation | 131.8% |
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| PBH Prestige Consumer Healthcare Inc. compare | 8.23% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −74.7% |
| SUPN Indivior Pharmaceuticals Inc. compare | −337.8% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on LQDA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement